Literature DB >> 8794845

Radiosensitivity of human breast cancer cell lines of different hormonal responsiveness. Modulatory effects of oestradiol.

M Villalobos1, D Becerra, M I Núñez, M T Valenzuela, E Siles, N Olea, V Pedraza, J M Ruiz de Almodóvar.   

Abstract

Treatments which inhibit or retard progression of the cell through the cell cycle have been reported to reduce the effectiveness of ionizing radiation by increasing cellular radioresistance. We studied cellular radiosensitivity and radiation-induced DNA damage (double-strand break, dsb) in both hormone-sensitive and non-sensitive human breast cancer cell lines. After 72h of culture in an oestradiol-deprived medium, MCF-7 BUS and T47D B8 breast cancer cells showed a significant delay in growth, whereas no effect was seen in EVSA-T cell line. In oestradiol-free medium, MGF-7 BUS cells were arrested mainly in G(zero)/G1 phase (85-90% in G(zero)/G1, 5-7% in S, and 6-8% in G2/M). The growth-delayed MCF-7 BUS cells showed reduced radiosensitivity (survival fraction at 2 Gy, SF2 = 63%; initial DNA damage 1.00 dsb/Gy/DNA unit) in comparison with proliferating cells (SF2 = 33%, initial DNA damage 2.70 dsb/Gy/DNA unit). The radio-protective effect of oestrogen deprivation was abolished by rescuing MCF-7 cells with oestrogen-containing medium. At 24h after rescue, MCF-7 BUS cells reached a cell cycle distribution close to that found under standard culture conditions and their radiosensitivity was correspondingly increased (SF2 = 40%, DNA damage = 2.52 dsb/Gy/DNA unit). Our findings indicate that: (1) sensitivity to radiation and the proportion of proliferating cells are probably related, and (2) differences in radiosensitivity reflect differences in radiation-induced DNA damage.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8794845     DOI: 10.1080/095530096145157

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  6 in total

1.  Estrogen enhanced cell-cell signalling in breast cancer cells exposed to targeted irradiation.

Authors:  Chunlin Shao; Melvyn Folkard; Kathryn D Held; Kevin M Prise
Journal:  BMC Cancer       Date:  2008-06-30       Impact factor: 4.430

2.  In vitro studies on the modification of low-dose hyper-radiosensitivity in prostate cancer cells by incubation with genistein and estradiol.

Authors:  Robert Michael Hermann; Hendrik Andreas Wolff; Hubertus Jarry; Paul Thelen; Carsten Gruendker; Margret Rave-Fraenk; Heinz Schmidberger; Hans Christiansen
Journal:  Radiat Oncol       Date:  2008-07-14       Impact factor: 3.481

Review 3.  Concurrent or Sequential Hormonal and Radiation Therapy in Breast Cancer: A Literature Review.

Authors:  Matthew J Cecchini; Edward Yu; Kylea Potvin; David D'souza; Michael Lock
Journal:  Cureus       Date:  2015-10-25

Review 4.  Estrogen Receptor Signaling in Radiotherapy: From Molecular Mechanisms to Clinical Studies.

Authors:  Chao Rong; Étienne Fasolt Richard Corvin Meinert; Jochen Hess
Journal:  Int J Mol Sci       Date:  2018-03-02       Impact factor: 5.923

5.  PCW-1001, a Novel Pyrazole Derivative, Exerts Antitumor and Radio-Sensitizing Activities in Breast Cancer.

Authors:  Minsung Kang; Navin Pandit; Ah-Young Kim; Suk Joon Cho; Young-Ju Kwon; Jiyeon Ahn; Kyu Myung Lee; Sangwook Wu; Jeong Su Oh; Kwan-Young Jung; Jae-Sung Kim
Journal:  Front Oncol       Date:  2022-03-29       Impact factor: 6.244

6.  A Single Institution Consensus on the Use of Sequential or Concurrent Hormonal Therapy for Breast Cancer Patients Receiving Radiation Therapy.

Authors:  Matthew J Cecchini; Edward Yu; Brian P Yaremko; R Gabriel Boldt; Kylea Potvin; Tracy Sexton; David D'Souza; Muriel Brackstone; Michael Lock
Journal:  Cureus       Date:  2016-04-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.